NewLimit scales manufacturing of its lead liver reprogramming medicine 100-fold and adds 4 more leads

NewLimit/Hepatocyte epigenetic reprogramming

NewLimit achieved >120-fold scaling in manufacturing of its lead hepatocyte medicine and discovered four more leads that restore function in old liver cells plus five payloads restoring function in endothelial cells for the first time.

• Manufacturing scale achieved through engineering solutions to fluid dynamics, enzymatic biology, and purification chemistry.
• 19 payloads demonstrated to make old hepatocytes look young; therapeutic benefits persisted after drug clearance.
• New vascular program identified 5 payloads restoring endothelial cell function plus 43 making old cells young-like.